NASDAQ:FUSN Fusion Pharmaceuticals (FUSN) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$21.55▼$21.5550-Day Range$21.38▼$21.5552-Week Range$2.31▼$21.60VolumeN/AAverage Volume1.69 million shsMarket Capitalization$1.83 billionP/E RatioN/ADividend YieldN/APrice Target$20.25 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends Get Fusion Pharmaceuticals alerts: Email Address Fusion Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.07 Rating ScoreUpside/Downside6.0% Downside$20.25 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.44) to ($1.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.01 out of 5 starsMedical Sector909th out of 910 stocksBiological Products, Except Diagnostic Industry155th out of 155 stocks 1.0 Analyst's Opinion Consensus RatingFusion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.07, and is based on 1 buy rating, 13 hold ratings, and no sell ratings.Amount of Analyst CoverageFusion Pharmaceuticals has received no research coverage in the past 90 days.Read more about Fusion Pharmaceuticals' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for FUSN. Previous Next 0.0 Dividend Strength Dividend YieldFusion Pharmaceuticals does not currently pay a dividend.Dividend GrowthFusion Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FUSN. Previous Next 0.6 News and Social Media Coverage Search Interest1 people have searched for FUSN on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Fusion Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fusion Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.75% of the stock of Fusion Pharmaceuticals is held by insiders.Percentage Held by Institutions72.85% of the stock of Fusion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fusion Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Fusion Pharmaceuticals are expected to decrease in the coming year, from ($1.44) to ($1.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fusion Pharmaceuticals is -15.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fusion Pharmaceuticals is -15.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFusion Pharmaceuticals has a P/B Ratio of 7.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About Fusion Pharmaceuticals Stock (NASDAQ:FUSN)Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.Read More Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade FUSN Stock News HeadlinesAugust 31, 2024 | msn.comJapan start-up aims to launch world's first steady-state fusion reactor in 2034August 7, 2024 | investing.comFusion Pharma (FUSN) Earnings Dates & ReportsSeptember 7, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…June 4, 2024 | prnewswire.comAcquisition of Fusion Pharmaceuticals CompletedMay 31, 2024 | prnewswire.comFusion Pharmaceuticals Receives Final Court Order Approving ArrangementMay 29, 2024 | prnewswire.comFusion Pharmaceuticals Shareholders Approve Acquisition by AstraZenecaMay 9, 2024 | prnewswire.comFusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate CancerMay 9, 2024 | businesswire.comFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSNSeptember 7, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…May 7, 2024 | investorplace.comFUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q1 2024May 7, 2024 | prnewswire.comFusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program UpdatesApril 26, 2024 | msn.comTop 4 Health Care Stocks That May Plunge This MonthApril 26, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Laboratory (LH), Fusion Pharmaceuticals (FUSN) and Integer Holdings (ITGR)April 25, 2024 | prnewswire.comFusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim OrderApril 19, 2024 | morningstar.comFusion Pharmaceuticals Inc Ordinary SharesApril 17, 2024 | finance.yahoo.comFusion Pharmaceuticals Inc. (FUSN) Stock Moves -0.09%: What You Should KnowApril 17, 2024 | msn.comTD Cowen Downgrades Fusion Pharmaceuticals (FUSN)April 11, 2024 | finance.yahoo.comFusion Pharmaceuticals Inc. (NASDAQ:FUSN) is definitely on the radar of institutional investors who own 46% of the companySee More Headlines Receive FUSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FUSN CUSIPN/A CIK1805890 Webfusionpharma.com Phone289-799-0891FaxN/AEmployees101Year FoundedN/APrice Target and Rating Average Stock Price Target$20.25 High Stock Price Target$24.00 Low Stock Price Target$15.00 Potential Upside/Downside-6.0%Consensus RatingHold Rating Score (0-4)2.07 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($1.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,900,000.00 Net Margins-4,136.55% Pretax Margin-5,084.07% Return on Equity-48.74% Return on Assets-36.87% Debt Debt-to-Equity Ratio0.21 Current Ratio10.64 Quick Ratio10.64 Sales & Book Value Annual Sales$2.07 million Price / Sales885.53 Cash FlowN/A Price / Cash FlowN/A Book Value$3.07 per share Price / Book7.02Miscellaneous Outstanding Shares85,060,000Free Float78,468,000Market Cap$1.83 billion OptionableOptionable Beta-0.69 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. John F. Valliant Ph.D. (Age 53)Founder, CEO & Director Comp: $911.34kMr. Mohit Rawat (Age 44)President & Chief Business Officer Comp: $706.08kMr. John J. Crowley CPA (Age 50)CFO & Compliance Officer Comp: $719.82kDr. Eric Burak Ph.D. (Age 59)Chief Technology Officer Comp: $638.04kDr. Christopher Paul Leamon Ph.D. (Age 58)Chief Scientific Officer Ms. Amanda CraySenior Director of Investor Relations & Corporate CommunicationsMs. Maria D. Stahl (Age 53)Chief Legal Officer Mr. Eric S. Hoffman Ph.D. (Age 54)Senior Vice President of Business Development Dr. Cara Ferreira Ph.D.Chief of StaffDr. Joanne SchindlerExecutive Vice President of Medical Director & Clinical DevelopmentMore ExecutivesKey CompetitorsY-mAbs TherapeuticsNASDAQ:YMABProgenics PharmaceuticalsNASDAQ:PGNXMeiraGTxNASDAQ:MGTXRevolution MedicinesNASDAQ:RVMDKrystal BiotechNASDAQ:KRYSView All CompetitorsInstitutional OwnershipCowen AND Company LLCSold 258,200 shares on 8/7/2024Ownership: 0.000%Equitec Proprietary Markets LLCSold 157,700 shares on 7/12/2024Ownership: 0.000%View All Institutional Transactions FUSN Stock Analysis - Frequently Asked Questions How were Fusion Pharmaceuticals' earnings last quarter? Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) announced its earnings results on Tuesday, November, 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.58) by $0.13. The company had revenue of $0.33 million for the quarter. Fusion Pharmaceuticals had a negative trailing twelve-month return on equity of 48.74% and a negative net margin of 4,136.55%. When did Fusion Pharmaceuticals IPO? Fusion Pharmaceuticals (FUSN) raised $126 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 8,400,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Fusion Pharmaceuticals' major shareholders? Fusion Pharmaceuticals' top institutional investors include Cowen AND Company LLC and Equitec Proprietary Markets LLC. Insiders that own company stock include John Valliant and Steven Gannon. View institutional ownership trends. What other stocks do shareholders of Fusion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fusion Pharmaceuticals investors own include Overstock.com (OSTK), U.S. Xpress Enterprises (USX), Camping World (CWH), DocuSign (DOCU), Pfizer (PFE), Pure Storage (PSTG) and CrowdStrike (CRWD). This page (NASDAQ:FUSN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fusion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.